Kigtropin est le nom de marque de l'humain créé synthétiquement,Kigtropin est la meilleure somatropine HGH sur le marché, les résultats les plus efficaces et les meilleurs qu'une personne puisse obtenir, kigtropin est conçu. Nous expédions la commande depuis les États-Unis, chyna, et UE. Nous sommes distributeur de?kigtropin HGH grossiste de? kigtropine HGH, S'il vous plaît obtenir plus de kigtropin HGH Chine (Continent) fabricants, exportateurs, Fournisseurs, des usines, Entreprises de Chine .
Kigtropin est une hormone de croissance humaine (hGH) Somatropine produite avec la technologie de l'ADN recombinant identique à la HGH produite naturellement par le corps.
Retard de croissance des enfants dû à un déficit endogène en hormone de croissance (GHD).
Chez les adultes présentant un déficit en hormone de croissance,KIGTROPIN réduit la masse grasse,augmente la masse musculaire et améliore l'énergie,vitalité et bien-être subjectif. Chez les patients souffrant de brûlures graves,Fonte musculaire associée au SIDA,ou subissant des opérations importantes,KIGTROPIN favorise la cicatrisation des plaies,atténue la réponse catabolique des protéines et améliore l'état de l'azote dans tout le corps après l'opération.
Kigtropin comes as a freeze dried white powder – 10 X 10 IU (3.3 mg) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg par jour. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg par jour. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg par jour. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg par jour.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
